User login
Key clinical point: A topical cream containing cultured autologous antimicrobial-producing coagulase-negative strain of Staphylococcus (CoNS-AM+) safely decreased Staphylococcus aureus colonization and improved disease severity in patients with atopic dermatitis (AD).
Major finding: At the end of treatment, CoNS-AM+ reduced S. aureus colonization on lesioned skin by 99.2% compared with the vehicle (mean of log10 ratio to baseline, −1.702 vs 0.671; P = .01), which persisted even 4 days after treatment (P = .03). On day 11, Eczema Area and Severity Index scores improved significantly in patients receiving CoNS-AM+ vs vehicle (P = .04). No serious adverse events were recorded in either group.
Study details: This was a double-blind, vehicle-controlled randomized clinical trial of 11 adult patients with moderate-to-severe AD randomly assigned to either CoNS-AM+ (n=5) or the vehicle (n=6).
Disclosures: This work was supported by grants from the National Institute of Health. Dr. Nakatsuji, Dr. Gallo, and Dr. Shafiq reported receiving grants and/or consulting fees from and holding patent/pending patent, and/or holding equity in various sources.
Source: Nakatsuji T et al. JAMA Dermatol. 2021 Jun 16. doi: 10.1001/jamadermatol.2021.1311.
Key clinical point: A topical cream containing cultured autologous antimicrobial-producing coagulase-negative strain of Staphylococcus (CoNS-AM+) safely decreased Staphylococcus aureus colonization and improved disease severity in patients with atopic dermatitis (AD).
Major finding: At the end of treatment, CoNS-AM+ reduced S. aureus colonization on lesioned skin by 99.2% compared with the vehicle (mean of log10 ratio to baseline, −1.702 vs 0.671; P = .01), which persisted even 4 days after treatment (P = .03). On day 11, Eczema Area and Severity Index scores improved significantly in patients receiving CoNS-AM+ vs vehicle (P = .04). No serious adverse events were recorded in either group.
Study details: This was a double-blind, vehicle-controlled randomized clinical trial of 11 adult patients with moderate-to-severe AD randomly assigned to either CoNS-AM+ (n=5) or the vehicle (n=6).
Disclosures: This work was supported by grants from the National Institute of Health. Dr. Nakatsuji, Dr. Gallo, and Dr. Shafiq reported receiving grants and/or consulting fees from and holding patent/pending patent, and/or holding equity in various sources.
Source: Nakatsuji T et al. JAMA Dermatol. 2021 Jun 16. doi: 10.1001/jamadermatol.2021.1311.
Key clinical point: A topical cream containing cultured autologous antimicrobial-producing coagulase-negative strain of Staphylococcus (CoNS-AM+) safely decreased Staphylococcus aureus colonization and improved disease severity in patients with atopic dermatitis (AD).
Major finding: At the end of treatment, CoNS-AM+ reduced S. aureus colonization on lesioned skin by 99.2% compared with the vehicle (mean of log10 ratio to baseline, −1.702 vs 0.671; P = .01), which persisted even 4 days after treatment (P = .03). On day 11, Eczema Area and Severity Index scores improved significantly in patients receiving CoNS-AM+ vs vehicle (P = .04). No serious adverse events were recorded in either group.
Study details: This was a double-blind, vehicle-controlled randomized clinical trial of 11 adult patients with moderate-to-severe AD randomly assigned to either CoNS-AM+ (n=5) or the vehicle (n=6).
Disclosures: This work was supported by grants from the National Institute of Health. Dr. Nakatsuji, Dr. Gallo, and Dr. Shafiq reported receiving grants and/or consulting fees from and holding patent/pending patent, and/or holding equity in various sources.
Source: Nakatsuji T et al. JAMA Dermatol. 2021 Jun 16. doi: 10.1001/jamadermatol.2021.1311.